http://www.medadnews.com/News/Index.cfm?articleid=289170
SAN DIEGO--(BUSINESS WIRE)--Nov 8, 2005 - Illumina, Inc. (NASDAQ: ILMN) announced today that it has signed a multi-phase genotyping services agreement to support colorectal cancer researchers funded by Cancer Research UK, the world's leading independent charity dedicated to cancer research. The multi-million dollar agreement extends over several years and includes two major phases. In the first phase of the project, Illumina's service group will conduct dense, whole-genome genotyping (greater than 500,000 single nucleotide polymorphisms, or SNPs, per sample) for at least 4,000 well-classified colorectal patients and controls. In the second phase, Illumina will genotype over 10,000 samples using a custom, multi-sample BeadChip that will enable analysis of 20,000 SNPs per sample. Both phases will use Illumina's Sentrix(R) Arrays and Infinium(TM) Assay with the option to employ related assay methods.
200409 200412 200501 200502 200503 200504 200505 200506 200507 200508 200509 200510 200511 200512 200601 200602 200603 200604 200605 200606 200607 200608 200609 200610 200611 200612 200701 200702 200703 200704 200705 200707 200708 200709 200710 200711 200712 200801 200802 200803 200804 200805 200806 200807 200808 200809 200810 200811 200812 200901 200902 200903 200904 200905 200906 200907 200908 200909 200912 201001 201002 201003 201004 201007 201009 201011 201102
Subscribe to Posts [Atom]